Hypera SA

“Hypera owns Brazil's most recognizable OTC pharma brands with 60%+ gross margins and market-leading distribution, but four years of acquisition-driven over-leverage, a founder-controlled governance structure that actively blocked a takeover premium for minorities, and mediocre post-goodwill ROIC (~8-11%) place this firmly in the mediocre compounder category. At 7.2x forward earnings the valuation reflects excessive fear, but the margin of safety is modest — not exceptional — because the business does not earn above its cost of equity in a high-Selic environment. The 2025-2026 deleveraging trajectory is the single most important near-term catalyst: if net debt/EBITDA reaches 2x and the EMS overhang resolves without a stock re-rating, the risk/reward improves materially. Until then, conviction is insufficient for a BUY.”